Processa Pharmaceuticals Inc. (PCSA) shares have tumbled to a 52-week low, touching down at $0.8, marking a significant downturn for the micro-cap company currently valued at just $2.68 million. According to InvestingPro analysis, the company maintains a WEAK financial health score, though it shows strong liquidity with a current ratio of 3.97. This latest price level reflects a stark contrast to the stock's performance over the past year, with Processa Pharmaceuticals experiencing a precipitous 1-year change of -79.82%. Investors are closely monitoring the stock as it navigates this challenging period, with the 52-week low serving as a critical indicator of the company's current market position. InvestingPro analysis reveals the company holds more cash than debt, though it's quickly burning through available funds. Subscribers can access 10 additional key insights about PCSA's financial position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.